Latest Conference Articles

Patients with a subtype of lymphoma may be able to exclude radiotherapy if they respond to chemoimmunotherapy, although more follow-up is needed to assess potential long-term toxicities.

Educated Patient® MPN Summit Novel Drugs And Combinations for MF Presentation: May 20, 2023

June 19th 2023, 1:00pm

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit Risk Stratification and Management of MF Presentation: May 20, 2023

June 18th 2023, 2:00pm

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit Polycythemia Vera Panel: May 20, 2023

June 17th 2023, 2:00pm

Watch Dr. Nikolai Podoltsev, Dr. Jerry Spivak and Amy Lane answer questions about polycythemia vera during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit On The Horizon For PV Management Presentation: May 20, 2023

June 16th 2023, 1:00pm

Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Study Shows ‘A Lot of Hope’ for Prostate Cancer Treatment

June 15th 2023, 9:00pm

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.

Pre- or Post-Transplant Xospata Shows Relapse-Free Survival Benefit in AML Group

June 15th 2023, 3:00pm

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Educated Patient® MPN Summit Current Management of PV Presentation: May 20, 2023

June 15th 2023, 1:00pm

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Educated Patient® MPN Summit Essential Thrombocythemia Panel: May 20, 2023

June 14th 2023, 1:00pm

Watch Dr. Lucia Masarova, Dr. Laura C. Michaelis and Celia Militz answer questions about essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

More CAR-T Cell Therapies Will ‘Ease Out the Shortage’

June 13th 2023, 3:00pm

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Educated Patient® MPN Summit Current Management and Trials on the Horizon in ET Presentation: May 20, 2023

June 13th 2023, 1:00pm

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Standard Approach for Inactive, Early CLL Remains a Wait-and-Watch Strategy

June 12th 2023, 9:00pm

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

Jakafi Improves Symptoms, Spleen Volume in Myelofibrosis

June 12th 2023, 3:00pm

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Educated Patient® MPN Summit ET Risk Stratification Presentation: May 20, 2023

June 12th 2023, 1:00pm

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Maintenance Darzalex Regimen Promising in Post-Transplant Myeloma

June 10th 2023, 6:00pm

Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.

Iclusig With Chemo ‘Should Be Standard of Care’ for ALL Subset

June 10th 2023, 3:00pm

Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.

Study Examines Calquence in Older CLL Population

June 9th 2023, 9:00pm

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

ctDNA May Help Predict Lung Cancer Outcomes, Guide Treatment

June 7th 2023, 3:00pm

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Maintenance Zejula Induces Antitumor Activity, Increases Survival in Advanced Ovarian Cancer

June 7th 2023, 1:00pm

Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.

Tumor Treating Fields With Standard of Care May Significantly Improve Survival in Metastatic NSCLC

June 6th 2023, 10:00pm

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

Adding Opdivo to Chemo May Prolong Survival in Advanced Hodgkin Lymphoma

June 6th 2023, 8:00pm

Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.

Enhertu Is Promising for Difficult-to-Treat Solid Cancers

June 6th 2023, 7:00pm

Adding Jemperli to Chemo Lengthens Time to Progression in Early Endometrial Cancer

June 6th 2023, 3:00pm

Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.

HER3-Directed Therapy Was Effective and Safe in Breast Cancer Subtype

June 6th 2023, 1:00pm

Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.

Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years

June 5th 2023, 10:00pm

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Lenvima Plus Keytruda ‘Stood the Test of Time’ for Kidney Cancer

June 5th 2023, 9:00pm

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Presurgical FOLFOX/Chemo as Effective as Chemoradiation in Rectal Cancer

June 5th 2023, 8:00pm

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.

Triplet Regimen Bests Single-Agent Cabometyx in Soft Tissue Sarcoma

June 5th 2023, 7:00pm

Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.

Vorasidenib May ‘Change the Treatment Paradigm’ for Low-Grade Glioma

June 5th 2023, 2:00pm

Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.

Side Effects Manageable From Talzenna/Xtandi Treatment in Prostate Cancer Subset

June 5th 2023, 1:00pm